Development of an in vitro colony formation assay for the evaluation of in vivo chemotherapy of a rat brain tumor.
An in vitro colony formation assay for the evaluation of in vivo brain tumor therapy has been developed. When plated, disaggregated cells derived from solid tumors proliferated to form relatively homogeneous colonies after a latency period of 2 to 6 days. Increasing concentrations of fetal calf serum enhanced colony-forming efficiency (CFE) with a plateau between 7 and 16%. Supplementation with either irradiated feeder cells (10(3) to 10(5) cells per dish), or medium conditioned by 1 to 3 days of in vitro incubation with the same cell line, doubled the CFE. The density of tumor cells (untreated or previously treated with chemotherapeutic agents) did not affect the CFE when a minimum of 10(4) total cells (tumor plus feeder) were plated. Therefore, in this system the optimal experimental conditions for evaluating chemotherapy and radiotherapy require incubation of disaggregated tumor cells for 12 days in medium containing 10% of fetal calf serum and enough feeder cells to provide a minimum of 10(4) cells per dish. The CFE for untreated tumors was 18 +/- 10% (+/-S.D.), demonstrating that there is significant biological variation. The assay appeared sensitive, with reproducible results, when applied to individual chemically treated tumors. An estimate of the percentage of clonogenic cells affected by in vivo chemotherapy may be obtained by comparing the CFE of cells from treated and untreated tumors. This assay can measure up to a 5 log(10) cell kill, and it should prove to be valuable in developing more effective regimens for the treatment of solid tumors in animals and man.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001769:Blood; D001932:Brain Neoplasms / Q000188:drug therapy*; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival; D002999:Clone Cells / Q000187:drug effects*; D003470:Culture Media; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D008297:Male; D009368:Neoplasm Transplantation; D009607:Nitrosourea Compounds / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D012509:Sarcoma / Q000188:drug therapy
D000970:Antineoplastic Agents; D003470:Culture Media; D009607:Nitrosourea Compounds